|
US3024257A
(en)
|
1961-04-10 |
1962-03-06 |
Frosst & Co Charles E |
Stable preparations of alkali metal salts of estrone sulfate
|
|
FR2340735A1
(fr)
|
1976-02-11 |
1977-09-09 |
Roussel Uclaf |
Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
|
|
IE52670B1
(en)
|
1981-03-03 |
1988-01-20 |
Leo Ab |
Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
|
|
DE3437232A1
(de)
|
1984-10-10 |
1986-04-17 |
Mack Chem Pharm |
Stabilisierte injektionsloesungen von piroxicam
|
|
US4782155A
(en)
|
1986-03-19 |
1988-11-01 |
Banyu Pharmaceutical Co., Ltd. |
Cephalosporin derivatives, processes for their preparation and antibacterial agents
|
|
SE8902076D0
(sv)
|
1989-06-09 |
1989-06-09 |
Pharmacia Ab |
Derivatives of quinoline-3-carboxanilide
|
|
HUT60458A
(en)
|
1991-02-01 |
1992-09-28 |
Sandoz Ag |
Process for producing benzyloxyphenyl derivatives and pharmaceutical compositions comprising same
|
|
US5139878A
(en)
|
1991-08-12 |
1992-08-18 |
Allied-Signal Inc. |
Multilayer film constructions
|
|
US5540934A
(en)
|
1994-06-22 |
1996-07-30 |
Touitou; Elka |
Compositions for applying active substances to or through the skin
|
|
CH687615A5
(de)
|
1994-09-07 |
1997-01-15 |
R W Johnson Pharmaceutical Res |
Tropen-Verpackung.
|
|
US5912349A
(en)
|
1997-01-31 |
1999-06-15 |
Pharmacia & Upjohn Company |
Process for the preparation of roquinimex
|
|
US20030124187A1
(en)
|
1997-02-14 |
2003-07-03 |
Smithkline Beecham Laboratoires Pharmaceutiques, |
Pharmaceutical formulations comprising amoxycillin and clavulanate
|
|
SE9801474D0
(sv)
*
|
1998-04-27 |
1998-04-27 |
Active Biotech Ab |
Quinoline Derivatives
|
|
US6077851A
(en)
|
1998-04-27 |
2000-06-20 |
Active Biotech Ab |
Quinoline derivatives
|
|
US6133285A
(en)
|
1998-07-15 |
2000-10-17 |
Active Biotech Ab |
Quinoline derivatives
|
|
SE9802550D0
(sv)
|
1998-07-15 |
1998-07-15 |
Active Biotech Ab |
Quinoline derivatives
|
|
SE9802549D0
(sv)
|
1998-07-15 |
1998-07-15 |
Active Biotech Ab |
Quinoline derivatives
|
|
US6121287A
(en)
|
1998-07-15 |
2000-09-19 |
Active Biotech Ab |
Quinoline derivatives
|
|
YU86001A
(sh)
|
1999-06-07 |
2004-07-15 |
Altana Pharma Ag. |
Novi preparat i oblik, u kojem se daje lek, koji sadrži aktivno jedinjenje labilno prema kiselini
|
|
US6395750B1
(en)
|
1999-10-25 |
2002-05-28 |
Active Biotech Ab |
Drugs for the treatment of malignant tumors
|
|
SE0002320D0
(sv)
*
|
1999-10-25 |
2000-06-21 |
Active Biotech Ab |
Malignant tumors
|
|
JP2002031610A
(ja)
|
2000-07-14 |
2002-01-31 |
Ajinomoto Co Inc |
生体分子複合体の界面残基を同定する方法
|
|
US6307050B1
(en)
|
2000-08-29 |
2001-10-23 |
R. T. Alamo Venture I Llc |
Method of synthesizing flosequinan from 4-fluoroanthranilic acid
|
|
US6802422B2
(en)
|
2000-12-12 |
2004-10-12 |
Multi-Comp, Inc. |
Sealed blister assembly
|
|
US6706733B2
(en)
|
2001-05-08 |
2004-03-16 |
Dainippon Ink And Chemicals, Inc. |
Quinolinone derivative formulation and its production method
|
|
US20030119826A1
(en)
|
2001-09-24 |
2003-06-26 |
Pharmacia Corporation |
Neuroprotective treatment methods using selective iNOS inhibitors
|
|
US6875869B2
(en)
|
2002-06-12 |
2005-04-05 |
Active Biotech Ab |
Process for the manufacture of quinoline derivatives
|
|
SE0201778D0
(sv)
|
2002-06-12 |
2002-06-12 |
Active Biotech Ab |
Process for the manufacture of quinoline derivatives
|
|
US7560557B2
(en)
|
2002-06-12 |
2009-07-14 |
Active Biotech Ag |
Process for the manufacture of quinoline derivatives
|
|
ITMI20021726A1
(it)
|
2002-08-01 |
2004-02-02 |
Zambon Spa |
Macrolidi ad attivita' antiinfiammatoria.
|
|
US7820145B2
(en)
|
2003-08-04 |
2010-10-26 |
Foamix Ltd. |
Oleaginous pharmaceutical and cosmetic foam
|
|
US7790197B2
(en)
|
2003-06-09 |
2010-09-07 |
Warner-Lambert Company Llc |
Pharmaceutical compositions of atorvastatin
|
|
US20040253305A1
(en)
|
2003-06-12 |
2004-12-16 |
Luner Paul E. |
Pharmaceutical compositions of atorvastatin
|
|
US20050271717A1
(en)
|
2003-06-12 |
2005-12-08 |
Alfred Berchielli |
Pharmaceutical compositions of atorvastatin
|
|
EP1694308A1
(en)
|
2003-10-30 |
2006-08-30 |
Lupin Ltd. |
Stable formulations of ace inhibitors and methods for preparation thereof
|
|
US8314124B2
(en)
|
2004-02-06 |
2012-11-20 |
Active Biotech Ab |
Crystalline salts of quinoline compounds and methods for preparing them
|
|
SE0400235D0
(sv)
|
2004-02-06 |
2004-02-06 |
Active Biotech Ab |
New composition containing quinoline compounds
|
|
AU2006253842A1
(en)
|
2005-06-02 |
2006-12-07 |
Glenmark Pharmaceuticals S.A. |
Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
|
|
DK1937642T3
(en)
|
2005-10-19 |
2014-12-15 |
Teva Pharma |
Crystals of sodium laquinimod and the process for its preparation
|
|
KR20080112300A
(ko)
|
2006-03-16 |
2008-12-24 |
제넨테크, 인크. |
Ｃｄ4 항체를 사용하여 루푸스를 치료하는 방법
|
|
EA018031B1
(ru)
*
|
2006-06-12 |
2013-05-30 |
Тева Фармасьютикал Индастриз, Лтд. |
Стабильные препараты лаквинимода
|
|
AU2007284337B2
(en)
|
2006-08-17 |
2012-07-19 |
University Of Chicago |
Treatment of inflammatory diseases
|
|
US20100260716A1
(en)
|
2007-10-23 |
2010-10-14 |
Ucb Pharma Gmbh |
Compounds for treating demyelination conditions
|
|
PT2682120T
(pt)
|
2007-12-20 |
2016-11-07 |
Teva Pharma |
Preparações de laquinimod estáveis
|
|
EP2318371A2
(en)
|
2008-07-01 |
2011-05-11 |
Actavis Group PTC EHF |
Novel solid state forms of laquinimod and its sodium salt
|
|
WO2010028015A2
(en)
*
|
2008-09-03 |
2010-03-11 |
Auspex Pharmaceuticals, Inc |
2-oxo-1,2-dihydro-quinoline modulators of immune function
|
|
TW201438738A
(zh)
|
2008-09-16 |
2014-10-16 |
建南德克公司 |
治療進展型多發性硬化症之方法
|
|
UY32427A
(es)
|
2009-02-13 |
2010-09-30 |
Boheringer Ingelheim Internat Gmbh |
Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
|
|
US20100260755A1
(en)
*
|
2009-04-09 |
2010-10-14 |
Medicinova, Inc. |
Ibudilast and immunomodulators combination
|
|
BR112012000568A2
(pt)
|
2009-06-19 |
2015-10-06 |
Teva Pharma |
tratamento da esclerose múltipla com laquinimod
|
|
JP5882208B2
(ja)
|
2009-07-30 |
2016-03-09 |
テバ ファーマシューティカル インダストリーズ リミティド |
ラキニモドによるクローン病の治療
|
|
AU2010282948C1
(en)
|
2009-08-10 |
2017-03-02 |
Active Biotech, Ab |
Treatment of BDNF-related disorders using laquinimod
|
|
US20130035390A1
(en)
*
|
2010-01-13 |
2013-02-07 |
Ramot At Tel-Aviv University Ltd. |
Treatment of multiple sclerosis
|
|
SI2542079T1
(sl)
|
2010-03-03 |
2014-08-29 |
Teva Pharmaceutical Industries Ltd. |
Zdravljenje revmatoidnega artritisa s kombinacijo lakvinimoda in metotreksata
|
|
CN102781239B
(zh)
|
2010-03-03 |
2015-01-21 |
泰华制药工业有限公司 |
使用拉喹莫德治疗狼疮关节炎
|
|
KR20130041193A
(ko)
|
2010-07-09 |
2013-04-24 |
테바 파마슈티컬 인더스트리즈 리미티드 |
5-클로로-4-하이드록시-1-메틸-2-옥소-n-페닐-1,2-다이하이드로퀴놀린-3-카복스아마이드, 염 및 그의 용도
|
|
KR20130092558A
(ko)
|
2010-07-09 |
2013-08-20 |
테바 파마슈티컬 인더스트리즈 리미티드 |
중수소화된 n-에틸-n-페닐-1,2-다이하이드로-4-하이드록시-5-클로로-1-메틸-2-옥소퀴놀린-3-카복스아마이드, 그의 염 및 용도
|
|
EP2463289A1
(en)
|
2010-11-26 |
2012-06-13 |
Almirall, S.A. |
Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
|
|
MX2013006464A
(es)
|
2010-12-07 |
2013-07-29 |
Teva Pharma |
Uso de laquinimod para reducir la fatiga, mejorada el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple.
|
|
EP2537517A1
(en)
|
2011-06-22 |
2012-12-26 |
Active Biotech AB |
Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
|
|
IN2014MN00333A
(enExample)
|
2011-07-28 |
2015-09-25 |
Teva Pharma |
|
|
JP2014521659A
(ja)
|
2011-07-28 |
2014-08-28 |
テバ ファーマシューティカル インダストリーズ リミティド |
ラキニモドおよびインターフェロンβを組み合わせた多発性硬化症の治療
|
|
JP2014530821A
(ja)
|
2011-10-12 |
2014-11-20 |
テバ ファーマシューティカル インダストリーズ リミティド |
ラキニモドおよびフィンゴリモドを組み合わせた多発性硬化症の治療
|
|
WO2013116657A1
(en)
|
2012-02-03 |
2013-08-08 |
Teva Pharmaceutical Industries Ltd. |
USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY
|
|
JP6215238B2
(ja)
|
2012-02-16 |
2017-10-18 |
テバ ファーマシューティカル インダストリーズ リミティド |
Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用
|
|
US20130259856A1
(en)
|
2012-03-27 |
2013-10-03 |
Teva Pharmaceutical Industries, Ltd. |
Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
|
|
TW201804997A
(zh)
|
2012-05-02 |
2018-02-16 |
以色列商泰瓦藥品工業有限公司 |
高劑量拉喹莫德(laquinimod)於治療多發性硬化症之用途
|
|
TW201350467A
(zh)
|
2012-05-08 |
2013-12-16 |
Teva Pharma |
Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
|
|
WO2014004733A1
(en)
|
2012-06-26 |
2014-01-03 |
The Regents Of The University Of California |
Composition for lupus nephritis and methods of making and using the same
|
|
AR091706A1
(es)
|
2012-07-11 |
2015-02-25 |
Teva Pharma |
Formulaciones de laquinimod sin agentes alcalinizantes
|
|
UY34896A
(es)
|
2012-07-12 |
2014-02-28 |
Teva Pharma |
Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina
|
|
TW201410244A
(zh)
|
2012-08-13 |
2014-03-16 |
Teva Pharma |
用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
|
|
TW201410243A
(zh)
|
2012-08-13 |
2014-03-16 |
Teva Pharma |
用於治療大麻素受體型１（ｃｂ１）媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
|